BIOA Overview

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Wall Street analysts forecast BIOA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOA is37.00 USD with a low forecast of 15.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BIOAGE Labs Inc revenue for the last quarter amounts to 2.77M USD, increased 91.04

BIOAGE Labs Inc. EPS for the last quarter amounts to -0.52 USD, increased 44.44

BIOAGE Labs Inc (BIOA) has 60 emplpoyees as of May 28 2026.

Today BIOA has the market capitalization of 753.47M USD.